Opinion|Videos|December 29, 2023
Clinical Data on the Approved JAK Inhibitors for Treatment of Myelofibrosis
Author(s)Christine Cooper, RN, BSN, Aaron Gerds, MD, MS
An expert discusses the four FDA-approved JAK inhibitors for myelofibrosis - ruxolitinib, fedratinib, pacritinib, and momelotinib.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on CURE
1
From Stage 4 to Survivor: Dan’s Pancreatic Cancer Journey
2
A Closet Full of Boobs and the Thought That Caught Me by Surprise
3
Giredestrant Improves Outcomes in ER+/HER2– Breast Cancer
4
Breaking Down the Prostate Cancer Treatment Renaissance
5
